Anúncio
Anúncio
FATE
Fate Therapeutics, Inc.
1.06
USDPatrocinado
-0.05
-4.05%
08 de jan., 15:40 UTC -5
Encerrado
Pós-Mercado
1.07
+0.01
+0.94%
Relatórios de Lucros FATE
Rácio de surpresa positiva
FATE separação 22 de 40 últimas estimativas.
55%
Próximo Relatório
Data do Próximo Relatório
03 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.21M
/-$0.27
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-30.52%
/--
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-34.96%
/-38.64%
Fate Therapeutics, Inc. earnings per share and revenue
On 13 de nov. de 2025, FATE reported earnings of -0.27 USD per share (EPS) for Q3 25, beating the estimate of -0.29 USD, resulting in a 9.06% surprise. Revenue reached 1.74 milhão, compared to an expected 1.57 milhão, with a 11.20% difference. The market reacted with a -4.59% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of -0.27 USD, with revenue projected to reach 1.21 milhão USD, implying an aumentar of 0.00% EPS, and diminuir of -30.52% in Revenue from the last quarter.
FAQ
What were Fate Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Fate Therapeutics, Inc. reported EPS of -$0.27, beating estimates by 9.06%, and revenue of $1.74M, 11.2% above expectations.
How did the market react to Fate Therapeutics, Inc.'s Q3 2025 earnings?
The stock price moved down -4.59%, changed from $1.04 before the earnings release to $0.99 the day after.
When is Fate Therapeutics, Inc. expected to report next?
The next earning report is scheduled for 03 de mar. de 2026.
What are the forecasts for Fate Therapeutics, Inc.'s next earnings report?
Based on 15
analistas, Fate Therapeutics, Inc. is expected to report EPS of -$0.27 and revenue of $1.21M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio